Graphite Bio

Kim Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Garrett brings more than 25 years of industry experience leading high-performing, cross-functional teams at global biopharmaceutical companies to advance the development and life-cycle management of pipeline and approved therapies. Karsen served as the chief executive officer of the Celgene Cellular Therapeutics division of Celgene Corporation and as executive vice president and chief operations officer of Celgene Corporation. Kim Drapkin is the Chief Executive Officer of Graphite Bio. Kristen Hege is a renowned physician-scientist and a pioneer in advancing cell therapies through clinical development to regulatory approval. Joe Jimenez is the former chief executive officer of Novartis, one of the world’s leading pharmaceutical companies. Matthew Porteus is an academic founder of Graphite Bio and a pioneer in the field of gene editing. Carlo Rizzuto is a seasoned biopharmaceutical business executive and investor with over 2 decades of diverse leadership experience.